Specific and long-lasting suppression of rat adjuvant arthritis by low-dose Mycobacterium butyricum.
We have tested the therapeutic effect of intraperitoneal injections of Mycobacterium butyricum on the development of adjuvant arthritis in rats and we have explored the specificity and the duration of effectivity of this treatment. Rats with induced arthritis were injected intraperitoneally with the causative antigen, Mycobacterium butyricum, at concentrations 10 times lower than the inducing one, on the 3rd and 10th day after arthritis induction. The severity of the disease was assessed on the basis of physical (arthritis index, paw swelling) and biochemical (serum interleukin-6) parameters. The treatment with Mycobacterium butyricum led to a significant suppression of adjuvant-induced arthritis. This therapeutic effect was both antigen-specific, because intraperitoneal aspecific inflammation did not prevent the disease, and long-lasting. The results obtained in this model confirm the possibility of modulating the autoimmune process even when the immunological response is already triggered, suggesting new therapeutic strategies, more suitable than preventive vaccination, in human autoimmune diseases.
Conforti
A
A
Istituto di Farmacologia, Facoltà di Medicina e Chirurgia, University of Verona, Policlinico B. Roma, Italy. Anita@farma.univr.it
Lussignoli
S
S
Bertani
S
S
Verlato
G
G
Ortolani
R
R
Bellavite
P
P
Andrighetto
G
G
D000818:Animals; D000942:Antigens, Bacterial / Q000627:therapeutic use*; D001169:Arthritis, Experimental / Q000276:immunology / Q000517:prevention & control*; D001327:Autoimmune Diseases / Q000276:immunology / Q000517:prevention & control*; D005620:Freund's Adjuvant / Q000276:immunology; D007274:Injections, Intraperitoneal; D015850:Interleukin-6 / Q000097:blood; D008297:Male; D009161:Mycobacterium / Q000276:immunology*; D051381:Rats; D011917:Rats, Inbred Lew
D000942:Antigens, Bacterial; D015850:Interleukin-6; D005620:Freund's Adjuvant